- Home
- VRNT vs NMRA Comparison
VRNT vs NMRA Comparison
Compare VRNT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNT
- NMRA
- Stock Information
- Founded
- VRNT 1994
- NMRA 2019
- Country
- VRNT United States
- NMRA United States
- Employees
- VRNT N/A
- NMRA N/A
- Industry
- VRNT EDP Services
- NMRA
- Sector
- VRNT Technology
- NMRA
- Exchange
- VRNT Nasdaq
- NMRA Nasdaq
- Market Cap
- VRNT 1.8B
- NMRA 1.6B
- IPO Year
- VRNT N/A
- NMRA 2023
- Fundamental
- Price
- VRNT $26.53
- NMRA $12.00
- Analyst Decision
- VRNT Buy
- NMRA Strong Buy
- Analyst Count
- VRNT 8
- NMRA 8
- Target Price
- VRNT $35.00
- NMRA $22.86
- AVG Volume (30 Days)
- VRNT 865.6K
- NMRA 423.9K
- Earning Date
- VRNT 09-04-2024
- NMRA 10-30-2024
- Dividend Yield
- VRNT N/A
- NMRA N/A
- EPS Growth
- VRNT N/A
- NMRA N/A
- EPS
- VRNT 0.67
- NMRA N/A
- Revenue
- VRNT $915,103,000.00
- NMRA N/A
- Revenue This Year
- VRNT $4.89
- NMRA N/A
- Revenue Next Year
- VRNT $5.25
- NMRA N/A
- P/E Ratio
- VRNT $39.60
- NMRA N/A
- Revenue Growth
- VRNT 3.03
- NMRA N/A
- 52 Week Low
- VRNT $18.41
- NMRA $8.33
- 52 Week High
- VRNT $38.17
- NMRA $21.00
- Technical
- Relative Strength Index (RSI)
- VRNT 31.47
- NMRA 58.89
- Support Level
- VRNT $24.84
- NMRA $11.03
- Resistance Level
- VRNT $33.55
- NMRA $12.47
- Average True Range (ATR)
- VRNT 0.95
- NMRA 0.62
- MACD
- VRNT -0.37
- NMRA 0.10
- Stochastic Oscillator
- VRNT 19.52
- NMRA 86.32
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries helps brands provide Boundless Customer Engagement. The company's solutions help iconic brands close the gap created when it lacks the resources required to deliver experiences that fulfill customer expectations. Geographically, it derives a majority of its revenue from the United States.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.